Cystic Fibrosis Patients Assert Health Care Rights

Certain elements are critical to the health care that patients with cystic fibrosis need.  The Cystic Fibrosis Engagement Network has identified those elements in its new Health Care Bill of Rights for Individuals with Cystic Fibrosis, released this week.

ICER Report Offers Little for Women with Endometriosis

Only one-fourth of the 6 million women with endometriosis could be treated with a new GnRH antagonist and still meet the Institute for Clinical and Economic Review’s budget threshold, according to a report released by the organization.  The new drug has shown promise in clinical trials to lessen the pain associated with endometriosis, which can cause painful menstrual periods and even infertility.

Access, Disparities Issues Dominate Cardiovascular Health Policy Summit

A massive stroke marked a serious change in the weather for Mark McEwen, whose familiar face brought viewers the weather forecast on the 1990s’ “CBS This Morning.” McEwen keynoted the May 15 Cardiovascular Health Policy Summit in Washington, DC, describing how he struggled to regain speech, mobility and fine motor skills.

Where President Trump, U.S. Senators & Physicians Align

New research suggests that President Donald Trump, U.S. senators and the country’s physicians may agree on at least one thing: the federal 340B drug pricing program deserves more scrutiny.  Designed to encourage care for indigent and underinsured patients, the program has ballooned into a revenue stream for growing hospital systems.

Huntington’s Disease Patients Aim for Parity

This month, patients with Huntington’s disease are asking for what worked for patients with ALS and other debilitating diseases–parity to accessing Medicare benefits.  The request is a focal point for May’s Huntington’s Disease Awareness Month.

How Policymakers Can Redefine Pain Management

More than 42,000 Americans died from an opioid overdose in 2016.  Meanwhile, millions of other Americans suffer from chronic pain. The situation poses a difficult question for policymakers: How do we meet the needs of pain patients without contributing to the national opioid crisis?

ICER’s Migraine Report Tells Familiar Story

It’s a new drug, but the same old story.  The Institute for Clinical and Economic Review recently reported that preventive treatments for migraine may not, in their interpretation, be cost effective.   Known as CGGRP inhibitors, the drugs offer patients and health care providers the chance to not just treat but prevent debilitating migraine headaches.